Sorafenib plus paclitaxel metronomic chemotherapy in adreno-cortical-carcinoma patients progressing after 1st or snd line cytotoxic chemotherapy - PAXO

• Conditions: ACC; MedDRA version: 9.1Level: SOCClassification code 10014698Term: Endocrine disorders; MedDRA version: 9.1Level: LLTClassification code 10001326Term: Adrenal carcinoma

• Registration Number: EUCTR2008-000759-91-IT
• Lead Sponsor: AZIENDA OSPEDALIERA S. LUIGI GONZAGA

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2008-07-28
• Last Update Posted: 19 March 2012

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 25

Inclusion Criteria

- histologically confirmed diagnosis of ACC
- locally advanced or metastatic disease not amenable to radical surgery resection
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

- history of prior malignancy
- severe renal insufficiency

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified